Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., . . . Smith, P. E. (2021). The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: An open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet.
Chicago Style CitationMarson, Anthony, et al. "The SANAD II Study of the Effectiveness and Cost-effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-label, Non-inferiority, Multicentre, Phase 4, Randomised Controlled Trial." Lancet 2021.
MLA CitationMarson, Anthony, et al. "The SANAD II Study of the Effectiveness and Cost-effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-label, Non-inferiority, Multicentre, Phase 4, Randomised Controlled Trial." Lancet 2021.